Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Sponsor: Ascletis Pharma (China) Co., Limited
Summary
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-01
Completion Date
2026-08
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
ASC30 tablets
ASC30 tablets administered orally once daily
Placebo
Placebo administered orally once daily
Locations (8)
Ascletis Clinical Site
Riverside, California, United States
Ascletis Clinical Site
San Jose, California, United States
Ascletis Clinical Site
Denver, Colorado, United States
Ascletis Clinical Site
Miami, Florida, United States
Ascletis Clinical Site
Miami, Florida, United States
Ascletis Clinical Site
Decatur, Georgia, United States
Ascletis Clinical Site
Springfield, Missouri, United States
Ascletis Clinical Site
San Antonio, Texas, United States